Have a feature idea you'd love to see implemented?
Let us know!
LEXX Lexaria Bioscience Corp
Price (delayed)
$2.16
Market cap
$34.15M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.44
Enterprise value
$25.83M
Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's
Highlights
Lexaria Bioscience's equity has soared by 130% YoY and by 55% from the previous quarter
The EPS has surged by 61% year-on-year and by 35% since the previous quarter
The company's quick ratio fell by 11% QoQ
Key stats
What are the main financial stats of LEXX
Market
Valuations
Earnings
Shares outstanding
15.81M
Market cap
$34.15M
Enterprise value
$25.83M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.75
Price to sales (P/S)
79.42
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
68.55
Revenue
$376,845
EBIT
-$4.83M
EBITDA
-$4.63M
Free cash flow
-$4.69M
Per share
Balance sheet
Liquidity
EPS
-$0.44
Free cash flow per share
-$0.34
Book value per share
$0.79
Revenue per share
$0.03
TBVPS
$0.69
Total assets
$10.02M
Total liabilities
$271,375
Debt
$142,587
Equity
$10.12M
Working capital
$8.94M
Debt to equity
0.01
Current ratio
58.27
Quick ratio
56.25
Net debt/EBITDA
1.8
Margins
Efficiency
Dividend
EBITDA margin
-1,227.3%
Gross margin
98.7%
Net margin
-1,281%
Operating margin
-1,226.1%
Return on assets
-84.1%
Return on equity
-82.9%
Return on invested capital
-418.3%
Return on capital employed
-48.9%
Return on sales
-1,281%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LEXX stock price
How has the Lexaria Bioscience stock price performed over time
Intraday
-1.82%
1 week
1.89%
1 month
-21.45%
1 year
71.43%
YTD
72.8%
QTD
-29.18%
Financial performance
How have Lexaria Bioscience's revenue and profit performed over time
Revenue
$376,845
Gross profit
$372,023
Operating income
-$4.62M
Net income
-$4.83M
Gross margin
98.7%
Net margin
-1,281%
The gross profit has soared by 59% YoY and by 5% from the previous quarter
The net margin rose by 43% year-on-year and by 12% since the previous quarter
The operating margin is up by 39% year-on-year and by 14% since the previous quarter
The net income has increased by 30% YoY and by 11% QoQ
Growth
What is Lexaria Bioscience's growth rate over time
Valuation
What is Lexaria Bioscience stock price valuation
P/E
N/A
P/B
2.75
P/S
79.42
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
68.55
The EPS has surged by 61% year-on-year and by 35% since the previous quarter
Lexaria Bioscience's equity has soared by 130% YoY and by 55% from the previous quarter
LEXX's P/B is 47% below its 5-year quarterly average of 5.2 and 36% below its last 4 quarters average of 4.3
LEXX's revenue is up by 23% year-on-year
The stock's price to sales (P/S) is 8% more than its 5-year quarterly average of 73.2 but 3.5% less than its last 4 quarters average of 82.3
Efficiency
How efficient is Lexaria Bioscience business performance
The return on sales rose by 43% year-on-year and by 12% since the previous quarter
The company's return on invested capital rose by 42% YoY and by 19% QoQ
Lexaria Bioscience's ROE has increased by 33% from the previous quarter and by 29% YoY
Lexaria Bioscience's ROA has increased by 29% from the previous quarter and by 26% YoY
Dividends
What is LEXX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LEXX.
Financial health
How did Lexaria Bioscience financials performed over time
The total assets has soared by 91% YoY and by 58% from the previous quarter
The total liabilities has dropped by 77% year-on-year but it is up by 33% since the previous quarter
The debt is 99% smaller than the equity
Lexaria Bioscience's equity has soared by 130% YoY and by 55% from the previous quarter
LEXX's debt to equity has shrunk by 75% YoY and by 50% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.